Pfizer Inc. (PFE)
| Previous Close | 40.38 |
| Open | 40.55 |
| Bid | 40.35 x 1300 |
| Ask | 40.36 x 4000 |
| Day's Range | 40.28 - 40.60 |
| 52 Week Range | 39.23 - 56.32 |
| Volume | |
| Avg. Volume | 23,071,668 |
| Market Cap | 226.16B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 23.60 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.64 (3.76%) |
| Ex-Dividend Date | Jan 26, 2023 |
| 1y Target Est | N/A |
- CNW Group
CIBC introduces additional Canadian Depositary Receipts ("CDRs")
CIBC today announced the addition of six new Canadian Depositary Receipts ("CDRs"), now listed on the NEO Exchange.
- Business Wire
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
NEW YORK, March 21, 2023--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2023 Performance Report, to be issued that morning.
- Business Wire
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
NEW YORK, March 16, 2023--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness. The AMDAC's vote, while not binding, will be considered by the FDA when making its dec
